In a precision oncology trial, the central laboratory is the operational gateway through which every eligible patient must pass, not merely a testing vendor. Effective central lab coordination requires three non-negotiable design decisions made before protocol lock: a turnaround time SLA based on result availability at the site (not at the lab), assay validation verified against the expected sample type and patient population, and an active result notification system rather than a passive portal model. Programs that treat central lab setup as a procurement exercise rather than a design decision pay for it in enrollment delays and data quality problems at closeout.
—
Why Does Central Lab Setup Define Enrollment Velocity?
Precision oncology trials depend on central laboratory infrastructure that most sponsors treat as a vendor relationship rather than a core operational design decision. That framing is the source of most of the problems.
A central lab in a biomarker-driven oncology trial is not simply a testing service. It is the operational gateway through which every eligible patient must pass. The design of that gateway — how samples are shipped, how results are communicated, how exceptions are managed, how turnaround commitments are enforced — directly determines enrollment velocity and data quality.
—
What Are the Three Central Lab Design Decisions That Matter Most?
1. What is the difference between lab turnaround time and site turnaround time?
Central labs routinely quote turnaround times that represent laboratory processing time — not the end-to-end time from sample receipt to result-in-hand at the site. The gap between these two figures, which includes sample transit time, accessioning, and result reporting, can easily add 3–5 days to a quoted 5-day turnaround. Sponsors should negotiate turnaround commitments based on result availability at the site, not result availability at the lab.
| Turnaround Time Type | What It Measures | Typical Gap vs. Quoted Time |
|---|---|---|
| Lab processing time (quoted) | Sample receipt → result in lab system | Baseline |
| End-to-end turnaround | Sample collection → result at site | +3–5 days (transit, accessioning, reporting) |
| Site-aware turnaround | Result in lab system → coordinator notified | +0–3 days depending on notification model |
| Contractually meaningful | Sample collection → coordinator notification | Should be the SLA basis |
2. Is the assay validated for your expected sample type and patient population?
Not all biomarker assays are validated for all sample types. A trial requiring FFPE tissue for a next-generation sequencing panel will encounter different failure modes — insufficient tumor cellularity, degraded DNA from archival material — than a trial using fresh biopsies or liquid biopsy methods. Assay performance data on the expected sample type from the expected patient population should be reviewed before the assay is locked as the eligibility test.
Operationally, fit-for-purpose biomarker qualification as a challenge that must be resolved early in trial development, noting that its value “will be assessed differently by different stakeholders” (Sitero oncology program data).
3. Is result communication designed as an active notification or a passive portal?
The standard lab portal model — where results are posted and the site is expected to log in and check — is operationally inadequate for biomarker-driven enrollment. Results should trigger an active notification to the site coordinator, with a defined escalation if the notification is not acknowledged within a specified timeframe. This is a contractual and systems design requirement, not a courtesy.
Kyle Hanson, Director of Clinical Operations, Sitero:
“The most common operational mistake is not fully developing tissue logistics prior to FPI, allowing for potential gaps in specimen management and analysis. Lab manuals may be a low priority in fast-moving start-up, which may lead to no real assessment of whether selected sites can actually execute same-day specimen processing or have the freezer capacity and courier relationships required. Specimen issues may lead to screen-fails and delays in patient enrollment — samples that arrive at the central lab hemolyzed, insufficient, or out of stability window. Each failed screen can delay a patient’s eligibility window by two to four weeks. Aggregated across a trial, poor specimen workflow design can add three to six months to enrollment timelines and meaningfully inflate per-patient costs.”
—
How Is Liquid Biopsy Changing Central Lab Operations?
The 2025 ASCO Annual Meeting featured landmark data on circulating tumor DNA (ctDNA) as an eligibility and stratification tool — including Guardant Health’s data on ctDNA-informed adjuvant decisions in colorectal cancer (ASCO 2025). As liquid biopsy assays become eligibility-defining rather than exploratory, the operational requirements shift: shorter turnaround times are achievable (blood draw vs. biopsy), but new workflows are needed for blood sample logistics, assay performance monitoring, and result integration with the RTSM at enrollment.
Three new operational requirements created by ctDNA-based eligibility:
- Blood sample cold chain and transit logistics to central lab
- Real-time assay performance monitoring (failure rates, invalid results by site)
- RTSM integration to gate enrollment on ctDNA result confirmation
—
How Should Multi-Biomarker Protocols Be Coordinated?
Some precision oncology trials require multiple biomarker tests — a companion diagnostic for eligibility plus exploratory genomic profiling for secondary analyses. Each test may use a different lab, a different assay, and a different sample type. The coordination overhead is real and requires explicit operational ownership.
A data management team that has designed EDC specifications for multi-biomarker protocols from the start will spend significantly less time in closeout remediation than one that adapted a single-test template. Sitero’s data management team builds biomarker data capture specifications from the protocol, including structured fields for multiple assay results, central and local lab data, and companion diagnostic findings — with edit checks that reflect the actual eligibility logic of the protocol rather than generic oncology templates (Sitero oncology program data).
Checklist: Central Lab Setup Requirements Before Protocol Lock
- [ ] Turnaround SLA defined as site-level result availability, not lab processing time
- [ ] Assay performance data reviewed for expected sample type (FFPE, fresh, liquid biopsy)
- [ ] Active result notification system specified contractually (not portal-only)
- [ ] Escalation path defined for delayed results or invalid assay runs
- [ ] Sample failure workflow documented (re-biopsy coordination, enrollment timeline impact)
- [ ] EDC specifications built for the actual multi-assay structure of the protocol
- [ ] Site coordinator training includes specific central lab interface procedures
Related Resources
Biomarker-Driven Oncology Trial Design
Oncology CRO Services & Technology
—
Frequently Asked Questions
Q: Should the sponsor or the CRO own the central lab contract negotiation?
The sponsor typically owns the central lab selection and master agreement, while the CRO manages the operational relationship — site kit supply, result notification, deviation tracking. The risk in this split is that operational requirements get under-specified in the master contract. The CRO should review and contribute to the contractual SLA terms before they are signed, not receive them as fixed parameters afterward.
Q: What happens when a central lab result is invalid or a sample fails QC?
The re-biopsy and re-sampling workflow must be pre-defined in the protocol and in site training. Sites that encounter a sample failure without a clear protocol path — can the patient be re-screened? Within what timeframe? Using the same or different sample type? — will take unplanned time to resolve the question, during which the patient may be lost to another trial or to disease progression.
Q: How do you manage central lab coordination across multiple countries with different import regulations?
Sample import and customs clearance for central lab shipments is a global trial logistics problem, not just a lab problem. Countries with strict biological sample import requirements can add 1–2 weeks to effective turnaround time. The central lab’s experience with the specific countries in your site network should be assessed during feasibility, not discovered after activation.
—
Planning an oncology trial with precision biomarker eligibility workflows?
Sitero has supported 200+ oncology studies across 67+ countries. Talk to an oncology trial expert to discuss your protocol.
—
References
- Sitero. Oncology Program Operational Data. Internal dataset. 200+ oncology studies across 67+ countries. sitero.com/oncology/
- Hanson K. Director of Clinical Operations, Sitero. Expert interview conducted for this article. April 2026.
Biomarker-driven oncology trials enroll slowly because eligibility depends on a chain of steps — tissue procurement, sample shipment, lab processing, result communication, and site decision — each owned by a [...]
Adaptive oncology trials fail operationally, not statistically. Learn what data readiness, RTSM configuration, and DSMB preparation actually require in execution.
